Clinical and therapeutic implications of Sprouty2 feedback dysregulation in BRAF V600E-mutation-positive papillary thyroid cancer

Surgery (United States)

Volumn 154, Issue 6, 2013, Pages 1239-1245

  Dultz, Linda A ^a   Dhar, Shumon ^a   Ogilvie, Jennifer B ^a   Heller, Keith S ^a   Bar Sagi, Dafna ^a   Patel, Kepal N ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SPROUTY PROTEIN; SPROUTY2 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FEEDBACK SYSTEM; FEMALE; GENE SILENCING; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MUTATION; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TISSUE MICROARRAY; TUMOR CELL LINE; TUMOR GROWTH;

ADULT; CARCINOMA; CARCINOMA, PAPILLARY; CELL LINE, TUMOR; FEEDBACK, PHYSIOLOGICAL; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHATIC METASTASIS; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE PROTEINS; MIDDLE AGED; MUTANT PROTEINS; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; RNA INTERFERENCE; THYROID NEOPLASMS;

EID: 84887993409     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2013.06.024     Document Type: Article

References (25)

1. L. Davies, and H.G. Welch Increasing incidence of thyroid cancer in the United States, 1973-2002 JAMA 295 2006 2164 2167
2. M.N. Nikiforova, and Y.E. Nikiforov Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis Expert Rev Mol Diagn 8 2008 83 95
3. Y.E. Nikiforov, and M.N. Nikiforova Molecular genetics and diagnosis of thyroid cancer Nat Rev Endocrinol 7 2011 569 580
4. M. Xing BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications Endocr Rev 28 2007 742 762
5. M. Xing, W.H. Westra, and R.P. Tufano BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer J Clin Endocrinol Metab 90 2005 6373 6379
6. L. Xu, J.L. Zhou, and M. Cohen Spry2 expression correlates with BRAF mutation in thyroid cancer Surgery 148 2010 1282 1287
7. K.C. Lee, C. Li, and E.B. Schneider Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery 152 2012 977 983
8. P. Soares, and M. Sobrinho-Simoes Cancer: small papillary thyroid cancers - is BRAF of prognostic value? Nat Rev Endocrinol 7 2011 9 10
9. J.K. Nam, C.K. Jung, and B.J. Song Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg 203 2012 436 441
10. F. Edwin, K. Anderson, C. Ying, and T.B. Patel Intermolecular interactions of Sprouty proteins and their implications in development and disease Mol Pharmacol 76 2009 679 691
11. H.J. Kim, L.J. Taylor, and D. Bar-Sagi Spatial regulation of EGFR signaling by Sprouty2 Curr Biol 17 2007 455 461
12. H.J. Kim, and D. Bar-Sagi Modulation of signalling by Sprouty: a developing story Nat Rev Mol Cell Biol 5 2004 441 450
13. J.M. Mason, D.J. Morrison, M.A. Basson, and J.D. Licht Sprouty proteins: multifaceted negative-feedback regulators of receptor tyrosine kinase signaling Trends Cell Biol 16 2006 45 54
14. P. Lito, B.D. Mets, and S. Kleff Evidence that sprouty 2 is necessary for sarcoma formation by H-Ras oncogene-transformed human fibroblasts J Biol Chem 283 2008 2002 2009
15. A. Watanabe, R. Cornelison, and G. Hostetter Tissue microarrays: applications in genomic research Expert Rev Mol Diagn 5 2005 171 181
16. S.M. Hewitt Design, construction, and use of tissue microarrays Methods Mol Biol 264 2004 61 72
17. R. Leboeuf, J.E. Baumgartner, and M. Benezra BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines J Clin Endocrinol Metab 93 2008 2194 2201
18. R.E. Schweppe, A.A. Kerege, and V. Sharma Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition Thyroid 19 2009 825 835
19. E.W. Joseph, C.A. Pratilas, and P.I. Poulikakos The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Proc Natl Acad Sci U S A 107 2010 14903 14908
20. P. Lito, C.A. Pratilas, and E.W. Joseph Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Cancer Cell 22 2012 668 682
21. I. Amit, A. Citri, and T. Shay A module of negative feedback regulators defines growth factor signaling Nat Genet 39 2007 503 512
22. S. Traverse, N. Gomez, and H. Paterson Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor Biochem J 288 1992 351 355
23. S.C. Brady, M.L. Coleman, and J. Munro Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation Cancer Res 69 2009 6773 6781
24. C.A. Pratilas, B.S. Taylor, and Q. Ye (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway Proc Natl Acad Sci U S A 106 2009 4519 4524
25. S. Chandarlapaty Negative feedback and adaptive resistance to the targeted therapy of cancer Cancer Discov 2 2012 311 319